Ventura Ignacio, Salcedo Nerea Pinilla, Pérez-Bermejo Marcelino, Pérez-Murillo Javier, Tejeda-Adell Manuel, Tomás-Aguirre Francisco, Legidos-García María Ester, Murillo-Llorente María Teresa
Molecular and Mitochondrial Medicine Research Group, School of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain.
Translational Research Center San Alberto Magno CITSAM, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain.
Int J Mol Sci. 2025 Feb 23;26(5):1908. doi: 10.3390/ijms26051908.
Breast cancer is the most clinically relevant pathology of the mammary gland and is currently the most diagnosed malignant disease among women worldwide. In breast cancer prevention, it is important to consider that the risk of developing the disease is not the same for the entire population. This pathology presents heterogeneous clinical manifestations and the most common classification is related to the following hormonal receptors: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and triple-negative (TNBC). Currently, a new class of therapy is being used for cancer treatment: anti-body-drug conjugates. A bibliographic search was performed by establishing keywords and then combining them using Boolean operators OR and AND. Thus, the search equation was formulated according to the PICO search question to be used in the PubMed database. Results: Fifteen studies that met the established inclusion criteria were analyzed, and their methodological quality was assessed using the Joanna Briggs Institute approach, demonstrating high reliability in the results obtained, the analyzed studies focus on the combination of adjuvant Pertuzumab + Trastuzumab with chemotherapy for the treatment of HER2-positive breast cancer. Scientific evidence suggests that the combination of pertuzumab and trastuzumab not only improves the survival of patients with HER2-positive breast cancer but also provides a safe and flexible treatment option.
乳腺癌是乳腺最具临床相关性的病理类型，目前是全球女性中诊断最多的恶性疾病。在乳腺癌预防方面，必须考虑到整个人口中患该疾病的风险并不相同。这种病理表现出异质性的临床表现，最常见的分类与以下激素受体有关：雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER2）和三阴性（TNBC）。目前，一类新的疗法正在用于癌症治疗：抗体药物偶联物。通过建立关键词，然后使用布尔运算符OR和AND将它们组合起来进行文献检索。因此，根据要在PubMed数据库中使用的PICO检索问题制定了检索方程。结果：分析了15项符合既定纳入标准的研究，并使用乔安娜·布里格斯研究所的方法评估了它们的方法学质量，结果显示所获得的结果具有高度可靠性，分析的研究集中于辅助性帕妥珠单抗+曲妥珠单抗与化疗联合用于治疗HER2阳性乳腺癌。科学证据表明，帕妥珠单抗和曲妥珠单抗联合使用不仅能提高HER2阳性乳腺癌患者的生存率，还提供了一种安全且灵活的治疗选择。
